BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,969.34
      0.35%
      US Tech 100
      20,266.40
      0.33%
      Dow Jones
      44,296.51
      0.97%
      Brent Oil
      74.085
      -0.92%
      Bitcoin
      98,143.21
      0.10%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Cue Biopharma Inc (CUE) Quote

      Cue Biopharma Inc

      Cue Biopharma Inc (CUE)

      Cue Energy Resources Limited
      1.02
      -0.01
      (-0.97%)
      Closed November 25 4:00PM
      Delayed by 15 minutes
      1.03
      0.01
      (0.98%)
      After Hours: 7:20PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.03
      Bid
      1.06
      Ask
      1.10
      Volume
      266,040
      1.01 Day's Range 1.08
      0.45 52 Week Range 3.2491
      Market Cap
      65.251M
      Previous Close
      1.03
      Open
      1.01
      Last Trade
      1
      @
      1.07
      Last Trade Time
      Financial Volume
      $ 282,049
      VWAP
      1.0602
      Average Volume (3m)
      785,049
      Shares Outstanding
      63,350,327
      Dividend Yield
      -
      PE Ratio
      -1.31
      Earnings Per Share (EPS)
      -0.8
      Revenue
      5.49M
      Net Profit
      -50.73M

      About Cue Biopharma Inc

      Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant ... Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.cuebiopharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Cue Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CUE. The last closing price for Cue Biopharma was $1.03. Over the last year, Cue Biopharma shares have traded in a share price range of $ 0.45 to $ 3.2491.

      Cue Biopharma currently has 63,350,327 shares outstanding. The market capitalization of Cue Biopharma is $65.25 million. Cue Biopharma has a price to earnings ratio (PE ratio) of -1.31.

      Ask ADVFN Intelligence (AI)

      CUE Latest News

      More News

      Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage...

      November 14 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 14 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 14 2024
      Edgar (US Regulatory)

      Cue Biopharma Announces Strategic Organizational Transition

      Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific...

      November 14 2024
      GlobeNewswire Inc.

      Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

      BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage...

      November 12 2024
      GlobeNewswire Inc.

      Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

      Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and...

      November 08 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      October 08 2024
      Edgar (US Regulatory)

      Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      October 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      October 04 2024
      Edgar (US Regulatory)

      Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

      BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage...

      October 04 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.47-31.33333333331.51.55991.027386001.1309893CS
      4-0.51-33.11688311691.541.98911.027405631.52239649CS
      120.297140.53759039430.73291.98910.457850491.2597558CS
      26-0.87-45.78947368421.91.98910.455694091.16084677CS
      52-1.36-56.90376569042.393.24910.454463671.57044953CS
      156-13.8-93.054619015514.8314.860.453579073.36628604CS
      260-9-89.730807577310.0335.50.453371517.99638871CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PDYNPalladyne AI Corporation
      $ 4.59
      (129.50%)
      		83M
      QMCOQuantum Corporation
      $ 9.11
      (126.62%)
      		39.41M
      NANano Labs Ltd
      $ 8.26
      (89.02%)
      		2.03M
      XCURExicure Inc
      $ 18.60
      (71.27%)
      		4.36M
      SKKSKK Holdings Limited
      $ 1.75
      (59.09%)
      		95.06M
      AMIXAutonomix Medical Inc
      $ 6.21
      (-54.07%)
      		897.51k
      CETXCemtrex Inc
      $ 0.1146
      (-41.74%)
      		22.89M
      MSWMing Shing Group Holdings Ltd
       5.90
      (-35.52%)
      		417.08k
      RMSGReal Messenger Corporation
      $ 3.09
      (-26.25%)
      		305.85k
      ENSCEnsysce Biosciences Inc
      $ 0.4414
      (-25.49%)
      		3.93M
      ELABElevai Labs Inc
      $ 0.0201
      (-0.50%)
      		425.38M
      NVDANVIDIA Corporation
      $ 141.95
      (-3.22%)
      		236.51M
      SMCISuper Micro Computer Inc
      $ 33.15
      (11.62%)
      		159.61M
      VRPXVirpax Pharmaceuticals Inc
      $ 0.5501
      (-6.72%)
      		159.39M
      SOUNSoundHound AI Inc
      $ 8.24
      (18.05%)
      		107.91M

      CUE Discussion

      View Posts
      Hawkeye_tt Hawkeye_tt 1 month ago
      TY for that quick dip/Algo dump op. Took advantage big time.
      GL all...

      Hawk
      👍️0
      boston127 boston127 2 months ago
      Momentum for CUE is waning,

      as measured by a 14-period Slow Stochastic Oscillator. This means that investors are less aggressive in their recent purchases and may even be taking profits in positions bought at lower prices.
      👍️0
      boston127 boston127 2 months ago
      The On Balance Volume indicator (OBV) is bullish.

      The slope of the indicator is positive and suggests that buyers are presently more active than sellers.Today's volume was heavier than usual, trading 2,320,021 shares, versus an average of 389,835 shares per day during the last twelve months.
      👍️0
      boston127 boston127 2 months ago
      Momentum for CUE is strongly bullish.

      The 14-period Slow Stochastic oscillator is above 80, the level which many analysts call overbought. This means that investors have been actively purchasing shares and driving the price higher.
      👍️0
      boston127 boston127 2 months ago
      I got in on Friday. Everything

      about the company is good. Gotta love it. They did not give up much to get that $11M in financing. Will buy on dips. Bought a little more today.
      👍️0
      Monksdream Monksdream 2 months ago
      CUE under $2
      👍️0
      Hawkeye_tt Hawkeye_tt 2 months ago
      Look at that Wkly candle ! Vol fantastic.
      LT outlook back on !

      Hawk
      👍️0
      Triple nickle Triple nickle 2 months ago
      CUE ready to win 1.02
      👍️0
      Hawkeye_tt Hawkeye_tt 2 months ago
      Strong recovery on news....future looking good here. Buy, hold LT...
      Hawk
      👍️0
      Monksdream Monksdream 5 months ago
      CUE new 52 week low
      👍️0
      Hawkeye_tt Hawkeye_tt 2 years ago
      CUE....this story grows quickly. Merck early investor.
      Last few wks it has been breaking out.
      $5 break next. More Partners want in, on top of Ono.

      Hawk
      👍️0
      conix conix 3 years ago
      CUE Insider Buy
      Cue Biopharma Aaron G.L. Fletcher Director Buy 735,000 shares @ $4.76 $3,498,600.00 3/31/2022
      👍️0

      Your Recent History

      NASDAQ
      CUE
      Cue Biopharma
      TG
      TWA
      Towa
      USOTC
      PARXF
      Parex Resources (PK)
      Delayed Upgrade Clock